Prostate cancer

By Sabiu Abdullahi

Scientists at Umeå University in Sweden, in collaboration with partner institutions, have developed an experimental drug that could slow the growth of aggressive prostate cancer and stop it from spreading to other parts of the body.

The findings, which were published in the journal Signal Transduction and Targeted Therapy, suggest the treatment could provide a new option for tackling metastatic prostate cancer.

Maréne Landström, Professor of Pathology at the Department of Medical Biosciences, Umeå University, said the research team identified the biological processes responsible for cancer cell growth, invasion and metastasis.

“The new drug has been developed to prevent metastasis, and we are very pleased and proud that we have been able to identify the mechanisms that drive cancer cell growth, invasiveness, and metastatic spread,” Landström said.

Prostate cancer is among the most commonly diagnosed cancers in men. Although many cases progress slowly and remain non-life-threatening, some become highly aggressive and spread to organs such as the lymph nodes and bones.

To address this form of the disease, the researchers created a fully human antibody made entirely from human proteins. They said the design makes it suitable for further development as a therapeutic treatment.

According to the study, preclinical tests showed that the antibody stopped tumour growth and prevented the spread of an aggressive form of prostate cancer. The researchers added that the treatment works through a newly identified mechanism, which they believe could also reduce the likelihood of side effects.

Landström described the findings as encouraging but stressed that further studies and regulatory approvals are required before the treatment can be used in patients.

“This is a promising step forward, but several important stages remain before the treatment can benefit patients,” she said.

“We still need to conduct additional safety studies, and the treatment must be approved by regulatory authorities in Europe or the United States.”

She added that the project seeks to improve survival rates and the quality of life of people living with advanced prostate cancer. She also credited years of collaboration among researchers, organisations and funding partners for the progress achieved.

The research team plans to investigate whether the same treatment can be applied to other solid tumours.

“The next step is to investigate whether this treatment can also be used against other types of solid tumors,” Landström said.

“We hope that our work will ultimately contribute to the development of a new cancer drug that can benefit patients.”

The study involved experts from the SciLifeLab Drug Discovery and Development Platform, which contributed to the development of the antibody. Additional support came from the Umeå Biotech Incubator at Umeå University, while MetaCurUm Biotech AB funded the development and testing of the experimental treatment.